Identification of Friend or Foe: The Laboratory Challenge of Differentiating M-Proteins from Monoclonal Antibody Therapies.

摘要: Background: Since the first monoclonal antibody (mAb) therapy hit market in 1996, number of disorders treated with this class therapeutics has seen tremendous growth, over 50 antibody-based currently approved for use US and Europe. This recently made profound progress treatment refractory multiple myeloma (MM). Treating MM mAbs will challenge laboratory9s ability to differentiate exogenous being used treat patients from endogenous associated disease. Content: An overview therapeutic (t-mAbs) developed is provided. The anticipated impact these therapies on patient care, laboratory testing, clinical research discussed. Efforts underway develop strategies technologies help laboratories address growing mAb interferences are reviewed. Summary: Laboratories can implement risk mitigation at preanalytical postanalytical phase testing reduce likelihood reporting false-positive M-protein results receiving t-mAbs. However, analytical current methods ill-suited between residual disease drugs. Mass spectrometry–based might be best positioned aid rapidly evolving landscape treatment.